ID | 63433 |
フルテキストURL | |
著者 |
Otani, Yoshihiro
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Yoo, Ji Young
Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston
Shimizu, Toshihiko
Department of Neurosurgery, Matsuyama Shimin Hospital
Kurozumi, Kazuhiko
Department of Neurosurgery, Hamamatsu University School of Medicine
ORCID
Kaken ID
publons
researchmap
Date, Isao
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Kaur, Balveen
Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston
|
抄録 | Despite current progress in treatment, glioblastoma (GBM) remains a lethal primary malignant tumor of the central nervous system. Although immunotherapy has recently achieved remarkable survival effectiveness in multiple malignancies, none of the immune checkpoint inhibitors (ICIs) for GBM have shown anti-tumor efficacy in clinical trials. GBM has a characteristic immunosuppressive tumor microenvironment (TME) that results in the failure of ICIs. Oncolytic herpes simplex virotherapy (oHSV) is the most advanced United States Food and Drug Administration-approved virotherapy for advanced metastatic melanoma patients. Recently, another oHSV, Delytact®, was granted conditional approval in Japan against GBM, highlighting it as a promising treatment. Since oncolytic virotherapy can recruit abundant immune cells and modify the immune TME, oncolytic virotherapy for immunologically cold GBM will be an attractive therapeutic option for GBM. However, as these immune cells have roles in both anti-tumor and anti-viral immunity, fine-tuning of the TME using oncolytic virotherapy will be important to maximize the therapeutic efficacy. In this review, we discuss the current knowledge of oHSV, with a focus on the role of immune cells as friend or foe in oncolytic virotherapy.
|
キーワード | Oncolytic virus
Immune cells
Glioma
|
備考 | This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10014-022-00431-8
|
発行日 | 2022-4-6
|
出版物タイトル |
Brain Tumor Pathology
|
巻 | 39巻
|
出版者 | Springer Science and Business Media LLC
|
開始ページ | 57
|
終了ページ | 64
|
ISSN | 1433-7398
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology 2022
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1007/s10014-022-00431-8
|
Citation | Otani, Y., Yoo, J.Y., Shimizu, T. et al. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathol 39, 57–64 (2022). https://doi.org/10.1007/s10014-022-00431-8
|
助成機関名 |
Ministry of Education, Culture, Sports, Science and Technology
|
助成番号 | 21K20803
|